Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while losing weight, offering a potential solution to one of the key problems that’s emerged with popular obesity shots.

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes that its position as a market leader for insulin products in the country could give it an edge.